Comparing Assay Strategies Across Bioanalytical, Biomarker, and Pharmaceutical Testing Frameworks

Pharmaceutical scientists face significant challenges in developing and validating bioanalytical, biomarker, and pharmaceutical assays due to fundamental differences in context of use and regulatory expectations. Although these assays may rely on common analytical platforms -- such as ligand binding assays, mass spectrometry, cell-based assays, the background matrix, regulatory requirements, rigor of validation, and reference material strategies differ substantially depending on the specific intended use.

Evidence of the Gap:

Recent regulatory guidance documents, including ICH M10 (2023), FDA's Bioanalytical Method Validation Guidance (2025) and ICH Q2(R2)/Q14 (2023) — provide distinct frameworks for bioanalytical testing, biomarker assays, and the assessment of the quality of drug substances and drug products also known as Chemistry, Manufacturing, and Controls (CMC). However, they offer limited direction for assays that serve dual purposes or transition between contexts. In addition, the absence of harmonized approaches to reference material selection, characterization, and lifecycle management across these applications creates substantial uncertainty. For example, scientists developing protein therapeutics often validate the same analytical platform multiple times using different criteria depending on whether the assay supports release testing, stability studies, pharmacokinetic assessments, or biomarker evaluation.

This gap is particularly pronounced in the selection and use of reference materials. CMC applications typically require highly characterized, traceable reference standards with defined acceptance criteria, while biomarker assays often utilize fit-for-purpose reference materials with different performance expectations, ideally reflecting endogenous analytes. Consequently, determining when and how to establish an appropriate reference material strategy — whether through pharmacopeial standards, well defined in-house reference materials, or commercially available calibrators — inconsistently approached and not yet fully harmonized across the industry.

This session will benefit pharmaceutical, bioanalytical, and biomarker scientists working with protein therapeutics and associated biomarker assays across all stages of drug development and manufacturing.

Primary Audience:
• Analytical development scientists responsible for biomarker assay development and validation
• CMC professionals working with biologics release testing and stability programs
• Bioanalytical scientists developing pharmacokinetic, pharmacodynamic, or immunogenicity assays
• Quality control/quality assurance professionals establishing analytical control strategies

Secondary Audience:
• Reference material coordinators managing standards programs
• Validation specialists designing validation and verification protocols
• Project managers overseeing analytical transfer between development phases
• Quality by Design practitioners implementing analytical control strategies
• Pharmacopeial standards developers working with reference materials

Statement of Track Applicability:
This submission is directly applicable to both the Bioanalytical and Pharmaceutical Analysis tracks, as it addresses assay strategies and considerations that meaningfully support activities across both domains. The content is intentionally structured to reflect shared scientific principles.

This presentation offers a comprehensive examination of assay development, validation, and reference material strategies across CMC, bioanalytical, and biomarker applications, highlighting key regulatory and context of use distinctions and opportunities for standardization.
The session will open with an example demonstrating how context of use informs selection of appropriate assay platforms, reference materials, and validation requirements. It will also introduce regulatory frameworks governing each application area, including ICH Q2(R2)/Q14 for CMC and FDA/EMA bioanalytical guidance for clinical applications.

The core content focuses on three critical areas:

Reference Material Strategies: Examination of pharmacopeial standards, certified reference materials, in-house reference standards, and working standards. The discussion covers characterization requirements, traceability expectations, stability programs, and lifecycle management approaches tailored to each application context.

Regulatory Requirements Comparison: A structured comparison of validation parameter expectations (accuracy, precision, linearity, etc.) across CMC versus bioanalytical and biomarker applications. This section also considers acceptance criteria, robustness, and considerations for regulatory submissions.

Translatability

Assessment: A practical framework for evaluating when assays developed for one purpose can be adapted for another, incorporating fit-for-purpose concepts, streamlined verification pathways, and risk-based decision-making aligned with Quality by Design principles.

This presentation provides a systematic comparison of regulatory expectations, assay validation requirements, and reference material strategies across CMC, bioanalytical, and biomarker contexts. Through real-world case studies and regulatory precedents, participants will gain practical frameworks that support both development and lifecycle management needs, make informed decisions on reference material selection, and determine when assay translatability is appropriate versus when independent development and validation are required.